Associated Papers
Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations.
Vargas-Hernández A et al.
The Journal of Allergy and Clinical Immunology, 2018
Select a paper to view details